A Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Enrolling By Invitation
18-99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The main purpose of this study is to test the efficacy and safety (benefit and risks) of itolizumab, when added to corticosteroids, as treatment for aGVHD.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Graft Versus Host Disease
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, aged 18 or older Active, clinically diagnosed, moderate or severe cGVHD per NIH Consensus Criteria
Updated on
01 Aug 2024.
Study ID: 850964
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
